Streetbeat News

Regulatory

LXRX

Lexicon Pharmaceuticals has completed screening for its Phase 2B study of LX9211, a treatment for diabetic peripheral neuropathic pain, and expects to complete enrollment ahead of schedule. Top-line data is now anticipated in Q1 2025, earlier than previously expected.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:03 pm

FSHP

Trading for an unspecified asset was halted at 7:55 a.m. ET due to pending news. The halt indicates that significant information is expected to be released, which could impact the asset's price.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:55 am

IRTC

iRhythm Technologies' shares rose following FDA clearance for design changes to its Zio AT device.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:52 am

IBKR

Interactive Brokers has filed a Form 8-K/A to disclose revised operating results for Q3, indicating adjustments to previously reported financial data.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:49 am

SNGX

Soligenix announced that the Hong Kong Patent Office has granted a patent for 'Systems And Methods For Producing Synthetic Hypericin'. This development could enhance Soligenix's intellectual property portfolio and potentially impact its market position.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:35 am

CTSO

Cytosorbents' De Novo medical device application for DrugSorb-ATR has been accepted by the FDA, with a decision expected in 2025. The device aims to reduce bleeding in patients on ticagrelor undergoing CABG surgery.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:20 am

BGC

BGC Group has agreed to acquire OTC Global Holdings in an all-cash transaction to expand its Energy, Commodities, and Shipping business. The deal is subject to regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:19 am

ALVO

TEVA

Alvotech and Teva have received FDA approval for SELARSDI, a biosimilar to Stelara, in a new presentation. The product is expected to launch in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:16 am

OCGN

Ocugen's OCU410ST gene therapy for Stargardt Disease progresses to Phase 2 trials after the Data and Safety Monitoring Board approved the enrollment. The high dose is determined as the maximum tolerated dose with no serious adverse events reported.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:10 am

THS

TreeHouse Foods has expanded its voluntary recall to include all waffle and pancake products due to potential contamination with Listeria monocytogenes. This recall could impact the company's reputation and sales in the short term.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 10:57 am